NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
26 trialsNCT02948426 2026-01-08
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT04442126 2025-05-23
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Terminated
NCT04633278 2025-05-11
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT04162873 2025-02-12
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Phase 2 Terminated
NCT04376502 2025-01-03
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
Baptist Health South Florida
Phase NA Terminated
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT03396471 2024-04-18
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT01098422 2021-08-24
A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver
University of California, San Diego
Phase NA Terminated
NCT03549338 2020-09-28
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Symphogen A/S
Phase 2 Terminated
NCT02089334 2020-06-30
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Rexahn Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT01431794 2020-01-22
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT02920450 2019-10-04
UF-STO-LUNG-002
University of Florida
Phase 1/2 Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT00570674 2017-11-13
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01184053 2017-06-14
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00576056 2017-02-15
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
University of Pittsburgh
Phase 2 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00564876 2015-02-23
TOP0706
Duke University
Phase 2 Terminated
NCT00989092 2014-01-29
Darbepoetin Alfa and Anemia of Cancer
Amgen
Phase 2 Terminated
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated